

Thank you for your interest

Lichen planus is thought to occur when your body's immune system mistakenly attacks the skin and/or lining of the mouth and other areas, often leading to persistent itching and rashes. But lichen planus isn't just about what you see on the skin. It can affect how you feel about yourself, interact with others, and go about your daily life. While topical treatments may provide temporary relief, results are often not as noticeable as people hope, and additional therapies may be needed.

That's why we're conducting the ELIPSI study – we're looking to see if an investigational medicine designed to target the underlying cause of lichen planus could help people living with the condition.



An investigational medicine is a medicine that has not yet been approved for use by the public. If any other clinical terms feel unfamiliar, please ask the study team. You can find their contact details on the back of this brochure. They'll be happy to help.

What happens next?

Taking part in a clinical study is a big decision, so please take your time to consider whether joining the ELIPSI study might be right for you. If you would like more information or have any questions, please contact the study team.

Study team contact details:



The ELIPSI study

Information about a clinical study for people living with lichen planus involving the skin



CG1A632C1201_ Study introduction multifold_V1_02.June26_Master (English)



Who can take part?

We're looking for around 260 people to join the ELIPSI study, who, in addition to other criteria:

- Are aged 18 years or over
- Have been diagnosed with lichen planus affecting the skin
- Have not had sufficient relief with at least one medication applied to the skin (called "topical medication") for lichen planus for at least 3 months, or have been told by their doctor that there is no suitable topical medication



What does taking part in the ELIPSI study involve?

